Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Design Therapeutics ( (DSGN) ) has issued an announcement.
On August 7, 2025, Design Therapeutics announced advancements in its GeneTAC® programs and reported its second-quarter financial results. The company highlighted early human pharmacokinetics data for DT-216P2, showing favorable translation from non-human primates to humans, and initiated a Phase 2 biomarker study for DT-168 in Fuchs Endothelial Corneal Dystrophy patients. Despite a clinical hold from the FDA on its DT-216P2 IND application, Design continues its Phase 1/2 trial outside the U.S. Financially, the company reported a net loss of $19.1 million for the quarter, with cash and securities totaling $216.3 million.
The most recent analyst rating on (DSGN) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.
Spark’s Take on DSGN Stock
According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.
Design Therapeutics has significant financial challenges due to its lack of revenue and profitability, which heavily weighs on its score. Despite a strong balance sheet and positive technical indicators suggesting short-term momentum, the negative valuation metrics and absence of earnings diminish its overall appeal. The stock is risky and reliant on future revenue growth for improvement.
To see Spark’s full report on DSGN stock, click here.
More about Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company focused on developing GeneTAC® gene targeted chimera small molecules to treat serious degenerative genetic diseases. The company’s pipeline includes clinical-stage programs for Friedreich ataxia and Fuchs endothelial corneal dystrophy, as well as preclinical programs for myotonic dystrophy type-1 and Huntington’s disease.
Average Trading Volume: 93,616
Technical Sentiment Signal: Hold
Current Market Cap: $230.5M
For an in-depth examination of DSGN stock, go to TipRanks’ Overview page.